VectorialDATA
Stocks/HCA

HCA — HCA Healthcare, Inc.

Health CareNorth AmericaUnited StatesBlockchain certified

Price when we picked it (Jun 26, 2026)

$388.84

Target: $505.00 (+17.7%)

P/E Ratio

14.8

P/E Forward

12.9

Dividend

0.72%

Market Cap

$95.17B

EPS

$29.02

Consensus

Buy

What they do

HCA Healthcare is the largest private hospital system in the United States, founded in 1968 in Nashville, Tennessee by Dr. Thomas Frist Sr. (father of former Senator Bill Frist) and Jack Massey. Today it operates 188 hospitals + more than 2,400 outpatient sites (surgery centers, freestanding ERs, urgent care, physician clinics, imaging) in 19–20 U.S. states + the United Kingdom. ~280,000 employees. CEO: Sam Hazen (Chairman + CEO since January 1, 2019, 41+ years at HCA). CFO: Mike Marks since May 2024 (~30 years at HCA).

Geographic footprint (heavy sunbelt concentration): Texas (73 hospitals) + Florida (49) = >50% of total. Other core markets: Tennessee (HQ), Virginia (HCA Virginia), Colorado (HCA HealthONE Denver), Utah/Idaho (MountainStar Healthcare), Kansas/Missouri, Las Vegas, Nashville (TriStar). UK operates 6 hospitals in London under HCA UK.

Flagship brands/systems: HCA Florida (largest network in the state), HCA Houston, HCA Virginia, HCA HealthONE (Colorado), MountainStar (Utah/Idaho), TriStar Health (Tennessee), and Sarah Cannon Research Institute — the oncology research arm with >4,500 clinical trial enrollments/year and >750 first-in-human studies/year, contributing to the majority of new oncology therapies approved by the FDA in the past decade (UK + US presence).

2025 revenue structure ($75.6B total, +6.4% YoY): acute-care hospitals ~75–80% of revenue, outpatient ~15–20%, other ~5%. ~50% of revenue comes from combined Medicare/Medicaid, ~40% from commercial/managed care, ~10% other (uninsured, self-pay). The outpatient segment (surgery centers, freestanding ERs, urgent care) is where HCA is growing fastest — higher margin, less regulated.

Aggressive historical capital return: HCA is one of the most prolific buyback programs in the S&P 500 — since 2017 it has retired >$50B in shares (more than 50% of current market cap). Combines a growing dividend (raised 8.3% in January 2026) with a $10B buyback program authorized.

Why we like it

HCA at $429.01 means buying the #1 U.S. hospital operator at a forward P/E of 12.94x — a historical discount vs. its own 5-year average (~14.5x), right when the market is over-pricing the headwind from ACA subsidy expiration and the One Big Beautiful Bill Act. Specific reasons:

  • Q1 2026 was cleaner than the pricing suggests — reported April 24, 2026: revenue $19.109B (+4.3% YoY) in line, EPS GAAP $7.15 (+10.9% YoY) in line with consensus, same-facility revenue per equivalent admission +3.1%. Weak volume (respiratory admissions -42% YoY due to a very weak flu season) is one-off, not structural.
  • FY2026 guidance reaffirmed: revenue $76.5–$80.0B, Adj EBITDA $15.55–$16.45B, diluted EPS $29.10–$31.50 = midpoint $30.30, implied fwd P/E ~14.2x on midpoint. If HCA hits the high end, fwd P/E falls to 13.6x.
  • Massive capital return quantified: new $10B buyback authorization announced January 27, 2026 (=10.5% of current market cap). Q1 2026: $1.571B in repurchases (3.157M shares), $9.179B remaining. Dividend raised +8.3% to $0.78/quarter ($3.12/year forward). Share retirement run-rate: ~5–7% per year = a compounding mechanism outside of operating growth.
  • ACA subsidy headwind already priced in: $150M Q1 + guided $600M–$900M FY2026 = midpoint $750M ÷ revenue $78B = ~1% impact. Real pain but contained. Uninsured admissions +16% YoY = HCA captures volume that previously paid through ACA. If Congress renews subsidies in Q3–Q4 2026 debate, there is reversal upside not priced in.
  • OBBBA Medicaid phase-down not until January 1, 2028: state-directed payments capped, but 10pp/year phase-down = 5 years of runway. HCA has time to reprice and shift mix. Tennessee (HCA's home state) had increased state-directed payments by +$3.2B before the law = high base going into phase-down.
  • Sarah Cannon Research as a hidden crown jewel: >4,500 oncology trial enrollments/year, >750 first-in-human studies/year, contributor to the majority of FDA oncology approvals in the past decade. Potentially worth $5–10B standalone in a spin-out — not priced in HCA.
  • Sunbelt concentration = structural demographics: TX+FL are the fastest-growing U.S. states (TX +1.5%/year, FL +1.2%/year), with an influx of retirees (medical consumption per capita 2–3x average). HCA holds the #1 hospital share in Houston, Dallas-Fort Worth, Austin, Miami, Tampa and Orlando. Demand is structurally rising.
  • 212,000 babies/year = ~5.9% of ALL U.S. births delivered in HCA hospitals. Irreplaceable OB volume.
  • Analyst consensus 19–27 analysts: ~37% Strong Buy + ~37% Buy + ~21% Hold; mean target ~$505 = +17.7% upside. Post Q1, several cut targets but maintained Buy.

Key Risk

The risks are specifically measurable:

  • ACA enhanced subsidy expiration confirmed January 1, 2026 — premiums more than doubled on average. Q1 2026 already cost $150M; HCA guided $600M–$900M FY2026 ($750M midpoint). ACA admissions -15% YoY. If uninsured admissions don't compensate (Q1: +16% YoY) and bad-debt expense surges, the hit could slide toward the high end. Without legislative renewal in 2026, FY2027 run-rate could be similar or worse.
  • One Big Beautiful Bill Act (signed July 4, 2025): CBO estimates >$1T in federal healthcare cuts + 10M more uninsured nationally. Caps state-directed Medicaid payments at 100% Medicare in expansion states / 110% in non-expansion; existing arrangements phase down 10 percentage points/year from January 1, 2028. Tennessee had increased state-directed payments by +$3.2B before the law = high base going into phase-down.
  • Operating margin visibly compressing: 12.0% Q1 2026 vs. 12.7% Q1 2025 = -70bps. If labor inflation (nursing wages, agency staff) accelerates + payer mix shifts toward expanded Medicaid (lower reimbursement), margins may keep compressing 50–100bps additionally in 2026–2027.
  • Respiratory volume -42% YoY in Q1 2026: hurts comparables — very weak flu season (not structural but weighs on the quarter). If 2026–27 season is also not strong, Q4 2026 comparables suffer.
  • Geographic concentration TX+FL >50%: hurricanes (Helene + Milton 2024 cost ~$250M total: $50M Q3 + ~$200M Q4 2024). 2025 season without a major new hit. 2026 season remains a recurring risk (June–November). A major hurricane in Houston or Tampa can erase $200–400M of revenue + repair capex.
  • Premium vs. peers: forward P/E 12.94 vs. Tenet (THC) and Universal Health (UHS) trading lower — HCA trades at a modest premium justified by scale/margins but narrative compression can equalize multiples.
  • Recurring legislative risk: every change of administration can bring new Medicare reimbursement cuts, surprise billing legislation (No Surprises Act), 340B drug pricing reform, and site-neutral payment reforms (HCA operates many hospital outpatient departments that receive higher payments than independent clinics — site-neutral would eliminate that premium).
  • Labor cost trends: nurse-to-patient staffing ratios (California already mandated, Massachusetts and NY proposing) increase mandatory headcount. Agency nursing rates still 30–40% above pre-pandemic. Healthcare professional salary inflation runs 4–5% annually vs. CPI ~2.5%.
  • Tort/litigation: no material new cases identified in the past 6 months, but healthcare is a structurally litigious industry — there are always class actions, billing fraud allegations (False Claims Act), antitrust scrutiny in markets where HCA holds >50% local share.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked HCA on May 4, 2026 at $429.01.

Full Research

HCA Healthcare (HCA) — Full Research

Price: $429.01 | P/E TTM: 14.78 | Forward P/E: 12.94 | Div Yield: 0.72% | Market Cap: $95.17B


What is HCA Healthcare?

HCA Healthcare is the largest private hospital system in the United States, founded in 1968 in Nashville, Tennessee by Dr. Thomas Frist Sr. (father of former Senator Bill Frist) and Jack Massey. Originally Hospital Corporation of America. Today it operates 188 hospitals + more than 2,400 outpatient sites (surgery centers, freestanding ERs, urgent care, physician clinics, imaging) in 19–20 U.S. states + the United Kingdom.

CEO: Sam Hazen (January 1, 2019, 41+ years at HCA). CFO: Mike Marks (May 2024).

Geographic Footprint

StateHospitals
Texas73
Florida49
Tennessee (HQ)~16
Virginia~13
Colorado~8
14 other states + UK~29

TX + FL = >50% of total = concentrated exposure to hurricanes and state Medicaid policy (state-directed payments).

Q1 2026 — Reported April 24, 2026

  • Revenue: $19.109B (+4.3% YoY), in line with consensus $19.08B
  • Diluted EPS GAAP: $7.15 (+10.9% YoY from $6.45). Non-GAAP consensus: $7.13
  • Same-facility admissions: +0.9% YoY
  • Same-facility equivalent admissions: +1.3% YoY
  • Same-facility revenue per equivalent admission: +3.1% YoY
  • Operating income: $2.29B / margin 12.0% (vs $2.33B / 12.7% in Q1 2025) — margin contracted
  • Cash from ops: $2.014B (+22.0% YoY)
  • Key headwind: respiratory admissions -42% YoY (very weak flu season)
  • Buybacks Q1: 3.157M shares for $1.571B; $9.179B available post Q1

FY2026 Guidance (reaffirmed in Q1)

MetricRange
Revenue$76.5–$80.0B
Adj EBITDA$15.55–$16.45B
Net income$6.5–$7.0B
Diluted EPS$29.10–$31.50

Capital Return — Recent Increase

  • Dividend raised from $0.72 → $0.78 quarterly announced January 27, 2026 (with Q4 2025 results). Forward annualized: $3.12/year (yield ~0.73% at current price).
  • New $10B buyback program authorized January 27, 2026.
  • Historical buybacks: HCA has retired >$50B in shares since 2017 (>50% of current market cap).

Macro Catalysts and Risks

ACA Enhanced Subsidies — Expired January 1, 2026

Congress did not renew them at end of 2025. Individual health premiums more than doubled on average. Q1 2026 impact on HCA: $150M. FY2026 guidance: $600M–$900M total hit (midpoint $750M ≈ ~1% of revenue). ACA admissions -15% YoY (low end of guided -15/–20% range). Uninsured admissions +16% YoY as partial offset.

One Big Beautiful Bill Act (signed July 4, 2025)

The CBO estimates >$1T in federal healthcare cuts + 10M more uninsured nationally. Limits state-directed Medicaid payments to 100% Medicare in expansion states / 110% in non-expansion; existing arrangements phase down 10 percentage points/year from January 1, 2028. Tennessee had increased state-directed payments by +$3.2B before the law.

Hurricanes (recurring risk)

Helene + Milton 2024: ~$250M total impact ($50M Q3 + ~$200M Q4 2024). 2025 season with no material reported hit. 2026 season (June–November) remains a risk.

Brands & Crown Jewels

  • HCA Florida — largest network in the state
  • HCA Houston / HCA Virginia / HCA HealthONE (Colorado)
  • MountainStar Healthcare (Utah/Idaho)
  • TriStar Health (Tennessee)
  • Sarah Cannon Research Institute — >4,500 oncology trial enrollments/year, >750 first-in-human studies/year. Contributed to the majority of FDA oncology approvals over the past decade. UK + US presence.

Anchor Facts

  • HCA delivers ~212,000 babies a year = ~5.9% of all U.S. births (CDC: ~3.6M births/year). More than any other health system in the country.
  • HCA holds the #1 hospital market share in Houston, Dallas-Fort Worth, Austin, Miami, Tampa and Orlando.

Analyst Consensus (May 2026)

  • Composite rating: Buy. MarketBeat (19 analysts): 37% Strong Buy + 37% Buy + 21% Hold + 5% Sell + 0% Strong Sell.
  • Mean target: ~$505 (TipRanks 19 analysts $510.21; broad consensus 27 $505.04; median 45 $490, range $368–$525).
  • Upside vs. $429.01: +17.7% to the mean target.
  • Post Q1 2026: several analysts cut targets (weak volumes) but maintained Buy rating.

Key Quantified Risks

  • ACA subsidy lapse: $600M–$900M FY2026 ($750M midpoint = ~1% revenue). Without legislative renewal, FY2027 run-rate similar.
  • OBBBA Medicaid phase-down: begins January 1, 2028, 10pp/year, over 5 years.
  • Operating margin compressed: -70bps Q1 2026 vs. Q1 2025.
  • TX+FL >50% concentration: hurricanes + state policy.
  • Labor cost inflation: nurse-to-patient ratios, agency rates 30–40% above pre-pandemic.

Thesis in One Line

Buy the #1 U.S. hospital operator at a forward P/E of 12.94x — a historical discount — with a new $10B buyback (10.5% of market cap), +8.3% dividend, and >$50B shares retired since 2017. ACA + OBBBA headwinds are priced in; sunbelt demographics + Sarah Cannon are not.

Research date: May 4, 2026 | Next review: Nov 2026

This is not financial advice.

More picks in Health Care

See all Health Care picks →

More picks from United States

See all picks from United States →
Researched: May 4, 2026Updated: May 4, 2026Next review: Nov 4, 2026

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.